Approves for use through 07/31/2008 CMS 0651-0331

U.S. Patient and Transformat Office, U.S. DePARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | Application Number | | | | | | | |
|--|------------|------------------------------|---------------------------|---------------------|---|---|--|---|--------|---|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) | | | | Filing Date | | | | | | |
| | | | | First Named | First Named Inventor Fra | | nk G. C. HOOGENRAAD | | | |
| | | | | Art Unit | | | | | | |
| | | | | Examiner Na | Examiner Name | | | | | |
| | | | | Attorney Doc | Attorney Docket Number | | PHNI 040111US | | | _ |
| | | | | raminey boo | Auditiey Docket Hulliber | | 111112310111101 | _ | | |
| | | | | | | | | | | |
| | | | | | PATENTS | | | | Remove | |
| | | | | U.S. | U.S.PATENTS | | | Mellove | | |
| Examiner Initial* | Cite No | Patent Number | Kind Code ¹ | Issue Date | Name of Patentee or Applicant of cited Document | | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear | | | |
| | 1 | 6614226 | B2 | 2003-09-02 | Wedeen | Wedeen | | all | | |
| | 2 | 6992484 | B2 | 2006-01-31 | Frank | | | all | | |
| If you wis | h to a | dd additional U.S. Pate | nt citatio | n information pl | ease click t | he A | dd button. | | Add | _ |
| | | | U.S.P | ATENT APPLI | CATION P | JBLK | CATIONS | | Remove | _ |
| Examiner Initial* | Cite No | Publication Number | Kind Code ¹ | Publication Date | | | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear | | | |
| | 1 | | | | | | | | | |
| If you wis | h to a | l dd additional U.S. Publ | lished An | polication citation | n informatic | n nle | ase click the Ad | i button | Add | _ |
| , | | | | FORFIGN PAT | | • | | | Remove | _ |
| Examiner Initial* | | | y Kind | Publication A | | Name of Patentee or Applicant of cited Document | | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear | | |
| | 1 | DE 101 12 096 | DE | A1 | 2002-09-2 | 6 | Gembris | | | Z |

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Application Number | Fing Date | Fing Date | Fing Cate | Fing Cate | Find Cate

| Examiner Initials* | Cite No | Include name of the author (in CAPITAL LETTERS), 8t6 of the article (when appropriate), 8t6 of the ite (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published. | | | | |
|---|------------|---|--|--|--|--|
| | 1 | FRANK, L.R.; Characterization of Anisotropy in High Angular Resolution Diffusion-Weighted MRI; 2002, MRM; 47:1083-1099. | | | | |
| | 2 | FRANK, L.R.; Anisotrophy in High Angular Resolution Diffusion-Weighted MRI; 2001; MRM; 45:935-939. | | | | |
| | 3 | TUCH, D.S.; High Angular Resolution Diffusion Imaging Reveals Intravoxel White Matter Fiber Heterogeneity; 2002; MRN; 48:577-582. | | | | |
| | 4 | ZHAN, W., et al.; Circular Spectrum Mapping for Intravoxel Fiber Structures Based on High Angular Resolution Apparent Diffusion Coefficients; 2003; MRM; 49:1077-1088. | | | | |
| If you wish to add additional non-patent literature document citation information please click the Add button Add | | | | | | |

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Patient Documents at year, USPTO, DOLL or MEPP D016.4. Epiter office half sweet for economic type to howher code (WIPO Standard S13, 3, "Far planese patient Comments, he activation to the year of the reign or the Emperor mater proceeds he sent in manner for the patient Comment."

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard S1.16 if possible. **Applicant is to place a check mark here if Empirish Intraques transferiors in attraction.

Application Number | Filing Date | Filing Date | Filing Date | Filing Mark | Filing Ma

CERTIFICATION STATEMENT

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/t1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(eV).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- .7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

| _ | | | |
|------------|--------------------|---------------------|------------|
| Signature | /Thomas M. Lundin/ | Date (YYYY-MM-DD) | 2006-07-31 |
| Name/Print | Thomas M. Lundin | Registration Number | 48979 |

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.